| Targeting the bone marrow microenvironment in multiple myeloma Y Kawano, M Moschetta, S Manier, S Glavey, GT Görgün, AM Roccaro, ... Immunological reviews 263 (1), 160-172, 2015 | 379 | 2015 |
| APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment YT Tai, C Acharya, G An, M Moschetta, MY Zhong, X Feng, M Cea, ... Blood, The Journal of the American Society of Hematology 127 (25), 3225-3236, 2016 | 301 | 2016 |
| BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer M Moschetta, A George, SB Kaye, S Banerjee Annals of Oncology 27 (8), 1449-1455, 2016 | 284 | 2016 |
| Engineered nanomedicine for myeloma and bone microenvironment targeting A Swami, MR Reagan, P Basto, Y Mishima, N Kamaly, S Glavey, S Zhang, ... Proceedings of the National Academy of Sciences 111 (28), 10287-10292, 2014 | 281 | 2014 |
| Metabolic signature identifies novel targets for drug resistance in multiple myeloma P Maiso, D Huynh, M Moschetta, A Sacco, Y Aljawai, Y Mishima, ... Cancer research 75 (10), 2071-2082, 2015 | 242 | 2015 |
| C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma AM Roccaro, A Sacco, C Jimenez, P Maiso, M Moschetta, Y Mishima, ... Blood, The Journal of the American Society of Hematology 123 (26), 4120-4131, 2014 | 224 | 2014 |
| SDF-1 inhibition targets the bone marrow niche for cancer therapy AM Roccaro, A Sacco, WG Purschke, M Moschetta, K Buchner, C Maasch, ... Cell reports 9 (1), 118-128, 2014 | 157 | 2014 |
| CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation AM Roccaro, Y Mishima, A Sacco, M Moschetta, YT Tai, J Shi, Y Zhang, ... Cell reports 12 (4), 622-635, 2015 | 136 | 2015 |
| Therapeutic targeting of the mTOR‐signalling pathway in cancer: benefits and limitations M Moschetta, A Reale, C Marasco, A Vacca, MR Carratù British journal of pharmacology 171 (16), 3801-3813, 2014 | 134 | 2014 |
| The developing story of predictive biomarkers in colorectal cancer S Boussios, MA Ozturk, M Moschetta, A Karathanasi, ... Journal of personalized medicine 9 (1), 12, 2019 | 128 | 2019 |
| The cancer glycome: carbohydrates as mediators of metastasis SV Glavey, D Huynh, MR Reagan, S Manier, M Moschetta, Y Kawano, ... Blood reviews 29 (4), 269-279, 2015 | 127 | 2015 |
| Role of endothelial progenitor cells in cancer progression M Moschetta, Y Mishima, I Sahin, S Manier, S Glavey, A Vacca, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (1), 26-39, 2014 | 125 | 2014 |
| The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma SV Glavey, S Manier, A Natoni, A Sacco, M Moschetta, MR Reagan, ... Blood, The Journal of the American Society of Hematology 124 (11), 1765-1776, 2014 | 120 | 2014 |
| Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin–positive metastatic human melanoma xenografts M Moschetta, F Pretto, A Berndt, K Galler, P Richter, A Bassi, P Oliva, ... Cancer research 72 (7), 1814-1824, 2012 | 111 | 2012 |
| Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review S Boussios, P Karihtala, M Moschetta, A Karathanasi, A Sadauskaite, ... Diagnostics 9 (3), 87, 2019 | 109 | 2019 |
| Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies MA Frassanito, L Rao, M Moschetta, R Ria, L Di Marzo, A De Luisi, ... Leukemia 28 (4), 904-916, 2014 | 109 | 2014 |
| Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond S Boussios, C Abson, M Moschetta, E Rassy, A Karathanasi, T Bhat, ... Drugs in R&D 20, 55-73, 2020 | 106 | 2020 |
| Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression Y Kawano, O Zavidij, J Park, M Moschetta, K Kokubun, TH Mouhieddine, ... The Journal of clinical investigation 128 (6), 2487-2499, 2018 | 95 | 2018 |
| Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. K AT, G SV, B NA, J A, G JL, M S, M M, M Y, R A, D A, L CJ, S A, H D, T YT, ... Mol Cancer Ther., 2018 | 92 | 2018 |
| Proteomic characterization of human multiple myeloma bone marrow extracellular matrix SV Glavey, A Naba, S Manier, K Clauser, S Tahri, J Park, MR Reagan, ... Leukemia 31 (11), 2426-2434, 2017 | 87 | 2017 |
Aldo RoccaroASST Spedali Civili di Brescia, Brescia, ItalyVerified email at asst-spedalicivili.it
